A study conducted by researchers in the United States has found no evidence to suggest that the messenger RNA (mRNA) present in the Pfizer-BioNTech and Moderna vaccines that protect against coronavirus disease 2019 (COVID-19) can be transferred to human breast milk.
The team’s analysis did not detect any vaccine-related mRNA in breast milk samples collected from six individuals up to 48 hours after being immunized with one of the vaccines.
Stephanie Gaw and colleagues from the University of California in San Francisco say the findings support recommendations from the World Health Organization (WHO) and the Academy of Breastfeeding Medicine (ABM) that lactating individuals who receive an mRNA-based vaccine should continue to breastfeed their infants uninterrupted.
However, clinical data from larger populations is needed to better estimate the effect of these vaccines on lactation outcomes, adds the team.
A pre-print version of the research paper is available on the medRxiv* server, while the article undergoes peer review.
This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources
Rollout of the mRNA-based vaccines has started in several countries
Several countries have begun to rollout mRNA-based COVID-19 vaccines that have recently been approved for emergency use.
The mRNA in these vaccines codes for a protein called “spike,” found on the surface of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes COVID-19.
This spike is the main structure the virus uses to infect host cells and a major target of the neutralizing antibodies that are generated following vaccination.
However, phase 3 clinical trials of the Pfizer-BioNTech and Moderna vaccines currently being rolled out did not include pregnant or lactating women, despite an increased risk of severe COVID-19 complications in this population group.
Consequently, no clinical data are available regarding the safety or efficacy of mRNA-based vaccines in this population.
The WHO advises that breastfeeding individuals accept a vaccine if they belong to a prioritized group such as healthcare workers and continue to breastfeed after receiving the vaccine. The ABM also states that there is little plausible risk that vaccine lipid particles would enter the bloodstream and breast tissue or that nanoparticles or mRNA would be transferred to breast milk.
However, some mothers have still chosen to decline vaccination, while others have opted to “pump and dump” breast milk for up to 72 hours post-vaccination, and some have stopped breastfeeding altogether.
What did the current study involve?
Human breast milk samples were collected from six individuals between 4 and 48 hours following vaccination with either the Pfizer-BioNTech BNT162b2 vaccine (n=5) or Moderna’s mRNA-1273 vaccine (n=1).
Total RNA was isolated from breast milk components, including cells, the supernatant and the fat layer.
The gold standard method of SARS-CoV-2 detection – reverse transcription-quantitative polymerase chain reaction (RT-qPCR) – was performed in triplicate using primers that specifically target the vaccines’ spike-coding mRNA.
The Moderna vaccine was “spiked into” pre-vaccine samples before RNA extraction to provide a positive control. Pre-vaccine samples that did not have the vaccine added served as negative controls.
What did the team find?
The researchers detected vaccine mRNA in the “spiked-in” pre-vaccine samples, with higher levels detected in the fat layer fraction.
However, milk samples collected from six individuals within 24 hours of vaccination and six serial milk samples collected at 4, 8, 22, 28, 33, and 48 hours post-vaccination showed no evidence of vaccine-related mRNA in any of the breast milk components tested.
What did the authors conclude?
“We show here that the mRNA from anti-COVID vaccines is not detected in human breast milk samples collected 4-48 hours post-vaccine,” says Gaw and colleagues.
The researchers say the findings support recommendations from the WHO and ABM that lactating women who receive an mRNA-based vaccine continue to breastfeed their infants uninterrupted.
However, “clinical data from larger populations need to be collected and analyzed to better estimate the effect of these vaccines on lactation outcomes,” advises the team.
This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources
Journal references:
- Preliminary scientific report.
Gaw S, et al. COVID-19 mRNA vaccine is not detected in human milk. medRxiv, 2021. doi: https://doi.org/10.1101/2021.03.05.21252998, https://www.medrxiv.org/content/10.1101/2021.03.05.21252998v1
- Peer reviewed and published scientific report.
Golan, Yarden, Mary Prahl, Arianna Cassidy, Christine Y. Lin, Nadav Ahituv, Valerie J. Flaherman, and Stephanie L. Gaw. 2021. “Evaluation of Messenger RNA from COVID-19 BTN162b2 and MRNA-1273 Vaccines in Human Milk.” JAMA Pediatrics, July. https://doi.org/10.1001/jamapediatrics.2021.1929. https://jamanetwork.com/journals/jamapediatrics/fullarticle/2781679.
Article Revisions
- Apr 7 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Oral spray-based vaccine is a potential alternative to antibiotic treatments for recurrent UTIs